Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui) and Kailera Therapeutics, Inc. (Kailera) have announced the presentation of six abstracts at the 85th Scientific Sessions of the American Diabetes Association (ADA). The event is scheduled to take place from June 20-23, 2025, in Chicago, IL. These abstracts will showcase the progress of various therapies in the companies' metabolic disease portfolio, including injectable and oral treatments.

The abstracts presented by Hengrui include:

• HRS9531
  • Phase 2 clinical trial of HRS9531 in participants with type 2 diabetes up to 32 weeks
  • Phase 1 clinical trial of HRS9531 in healthy participants
  • Phase 2 clinical trial of HRS9531 in adults with obesity without diabetes up to 52 weeks
  • Phase 2 clinical trial of HRS9531 high dose (8 mg) in adults with obesity or overweight without diabetes
• HRS-7535
  • Phase 2 clinical trial of HRS-7535 in adults with type 2 diabetes
  • Phase 2 clinical trial of HRS-7535 in adults with obesity without diabetes

All abstracts will be available online in the journal Diabetes® and on the Kailera website post-congress. More details can be found on the ADA website.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a global pharmaceutical company with a focus on research, development, and commercialization of high-quality medicines. On the other hand, Kailera Therapeutics, Inc. is a clinical-stage biopharmaceutical company working on innovative therapies for obesity and related conditions.

For more information about Hengrui Pharma and Kailera Therapeutics, visit their respective websites.